Immunovant, Inc. Common Stock (IMVT) is a publicly traded Healthcare sector company. As of July 22, 2026, IMVT trades at $39.07 with a market cap of $8.12B and a P/E ratio of -14.15. IMVT moved -1.10% today. Year to date, IMVT is +53.62%; over the trailing twelve months it is +117.67%. Its 52-week range spans $12.72 to $41.23. Analyst consensus is strong buy with an average price target of $49.60. Rallies surfaces IMVT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest IMVT news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $39.07 |
| Market Cap | $8.12B |
| P/E Ratio | -14.15 |
| EPS | $-2.77 |
| Dividend Yield | 0.00% |
| 52-Week High | $41.23 |
| 52-Week Low | $12.72 |
| Volume | 586.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-505.61M |
| Gross Margin | 0.00% |
10 analysts cover IMVT: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $49.60.